Shionogi & Co., Ltd. has a beta of 0.21 ... Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an ...

Shionogi has prior experience in Covid-19 drug development. In 2024, the company’s antiviral drug Xocova (ensitrelvir) received full approval in Japan, but the Phase III SCORPIO-HR trial ...

Shionogi has prior experience in Covid-19 drug development. In 2024, the company’s antiviral drug Xocova (ensitrelvir) received full approval in Japan, but the Phase III SCORPIO-HR trial studying the ...

In addition to S-892216, Shionogi continues its extensive global development program for the novel COVID-19 oral antiviral ensitrelvir (generic name: ensitrelvir fumaric acid, Code No.: S-217622), ...

Japanese drugmaker Shionogi (OTCPK:SGIOY) said a Phase 3 study has shown its antiviral drug Xocova was effective in reducing the risk of developing symptomatic COVID-19 infection in those exposed ...

Ensitrelvir, known commercially as Xocova, showed a statistically significant reduction in participants with symptomatic infection after exposure to household contacts with COVID, Shionogi said in ...

TOKYO (Reuters) – Japan’s Shionogi & Co said on Tuesday a global, late-stage study showed its pill-based treatment for COVID-19 was effective in reducing transmission of the disease. Ensitrelvir, ...

Shionogi's ensitrelvir pill for Covid-19 missed the trial endpoint but demonstrated a strong antiviral effect. Xocova aimed for $2B annual sales and early 2025 US approval, competing with Pfizer's ...

WHY IT'S IMPORTANT Shionogi said previously it expected the pill, known commercially as Xocova, to deliver $2 billion in annual sales if it secured U.S. approval. Xocova would compete with Pfizer ...

Outside Japan, Xocova is also approved in Singapore. Sanofi keeps Novavax afloat with $1.2B bet on its vaccine platform Despite the misfire in SCORPIO-HR, Shionogi said that a pre-defined ...

TOKYO, May 13 (Reuters) - Japan's Shionogi & Co (4507.T), opens new tab said on Monday its pill-based treatment for COVID-19 did not meet the primary endpoint of showing a statistically ...

Its product portfolio includes Fetroja, Cabenuva and Apretude, Xocova, Finibax, Xofluza, and Tivicay. On April 15, SGIOY’s subsidiary, Taiwan Shionogi & Co., Ltd., received approval for a supplemental ...